The percentage of patients with high expression of SRCIN1 was higher in the ER-positive breast cancer (53.4%, p < 0.01) and PR-positive breast cancer (53.6%, p <0.05) groups than in the ER-negative and PR-negative groups. Here, SRCIN1 is linked to breast cancer.